$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414031366 Filed on May 15, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$949.5K	$1.134M	$1.251M
YoY Change	-23.43%	-9.36%	-5.0%
Cost Of Revenue	$1.090M	$1.083M	$1.066M
YoY Change	-0.91%	1.67%	-4.27%
Gross Profit	-$136.2K	$50.91K	$185.9K
YoY Change	-197.26%	-72.62%	-8.97%
Gross Profit Margin	-14.34%	4.49%	14.85%
Selling, General & Admin	$990.0K	$886.3K	$854.9K
YoY Change	1.02%	3.67%	2.4%
% of Gross Profit		1741.03%	459.85%
Research & Development	$200.0K	$153.6K	$155.1K
YoY Change	11.11%	-0.98%	17.32%
% of Gross Profit		301.75%	83.45%
Depreciation & Amortization	$180.0K	$170.0K	$180.0K
YoY Change	-5.26%	-5.56%	-14.29%
% of Gross Profit		333.95%	96.82%
Operating Expenses	$1.180M	$1.040M	$1.010M
YoY Change	1.72%	2.96%	4.44%
Operating Profit	-$1.316M	-$989.0K	-$824.1K
YoY Change	29.04%	20.01%	8.03%
Interest Expense	-$360.0K		$110.0K
YoY Change	-1300.0%		-47.62%
% of Operating Profit
Other Income/Expense, Net		-$1.094M	$109.1K
YoY Change		-1103.31%	-48.05%
Pretax Income	-$1.680M	-$2.080M	-$720.0K
YoY Change	69.7%	188.89%	30.91%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.678M	-$2.083M	-$715.0K
YoY Change	69.48%	191.37%	29.33%
Net Earnings / Revenue	-176.7%	-183.67%	-57.14%
Basic Earnings Per Share
Diluted Earnings Per Share	-$31.03K	-$48.93K	-$20.80K
COMMON SHARES
Basic Shares Outstanding	54.39M shares	41.54M shares	34.61M
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.68M	$23.70M	$3.680M
YoY Change	509.66%	544.02%	46.03%
Cash & Equivalents	$7.680M	$23.70M	$3.684M
Short-Term Investments	$10.00M
Other Short-Term Assets	$26.69K	$210.0K	$210.0K
YoY Change	0.0%	0.0%	23.53%
Inventory	$359.7K	$387.0K	$357.0K
Prepaid Expenses
Receivables	$913.0K	$805.3K	$830.0K
Other Receivables	$53.08K	$0.00	$10.00K
Total Short-Term Assets	$19.21M	$25.11M	$5.092M
YoY Change	332.41%	393.03%	27.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.018M	$1.183M	$1.853M
YoY Change	-39.56%	-36.15%	-28.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.400M
YoY Change
Other Assets	$264.1K	$258.6K	$293.6K
YoY Change	-4.5%	-11.91%	-2.03%
Total Long-Term Assets	$7.334M	$2.093M	$2.797M
YoY Change	180.83%	-25.2%	-21.94%
TOTAL ASSETS
Total Short-Term Assets	$19.21M	$25.11M	$5.092M
Total Long-Term Assets	$7.334M	$2.093M	$2.797M
Total Assets	$26.55M	$27.20M	$7.890M
YoY Change	276.3%	244.74%	3.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$570.0K	$610.0K	$370.0K
YoY Change	32.56%	64.86%	5.71%
Accrued Expenses	$580.0K	$410.0K	$280.0K
YoY Change	61.11%	46.43%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.154M	$1.021M	$649.3K
YoY Change	45.54%	57.21%	3.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.440M	$1.530M	$910.0K
YoY Change	60.0%	68.13%	12.35%
Total Long-Term Liabilities	$1.440M	$1.530M	$910.0K
YoY Change	60.0%	68.13%	12.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.154M	$1.021M	$649.3K
Total Long-Term Liabilities	$1.440M	$1.530M	$910.0K
Total Liabilities	$2.593M	$2.546M	$1.555M
YoY Change	53.54%	63.74%	8.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.05M	-$56.37M	-$51.10M
YoY Change	11.44%	10.32%	8.65%
Common Stock	$54.70K	$54.18K	$34.61K
YoY Change	58.02%	56.54%	18.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.390K	$8.390K	$8.390K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	13.20K shares	13.20K shares	13.20K shares
Shareholders Equity	$23.96M	$24.65M	$6.335M
YoY Change
Total Liabilities & Shareholders Equity	$26.55M	$27.20M	$7.890M
YoY Change	276.3%	244.74%	3.95%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$1.678M	-$2.083M	-$715.0K
YoY Change	69.48%	191.37%	29.33%
Depreciation, Depletion And Amortization	$180.0K	$170.0K	$180.0K
YoY Change	-5.26%	-5.56%	-14.29%
Cash From Operating Activities	-$990.0K	-$500.0K	-$760.0K
YoY Change	25.32%	-34.21%	-6.17%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$15.40M	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$15.42M	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	390.0K	19.79M	0.000
YoY Change	3800.0%
NET CHANGE
Cash From Operating Activities	-990.0K	-500.0K	-760.0K
Cash From Investing Activities	-15.42M	0.000	0.000
Cash From Financing Activities	390.0K	19.79M	0.000
Net Change In Cash	-16.02M	19.29M	-760.0K
YoY Change	1953.85%	-2638.16%	-10.59%
FREE CASH FLOW
Cash From Operating Activities	-$990.0K	-$500.0K	-$760.0K
Capital Expenditures	-$20.00K	$0.00	$0.00
Free Cash Flow	-$970.0K	-$500.0K	-$760.0K
YoY Change	22.78%	-34.21%	-1.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
	isr	Class Of Warrant Or Right Corrected ClassOfWarrantOrRightCorrected	10869	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54392781	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
	dei	Trading Symbol TradingSymbol	isr
	dei	Document Type DocumentType	10-Q
	isr	Class Of Warrant Or Right Corrected In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCorrectedInPeriodExercisePriceOfWarrantsOrRights	0.94
	isr	Class Of Warrant Or Right Exercised In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedInPeriodExercisePriceOfWarrantsOrRights	0.86
	isr	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	5648738	shares
	isr	Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightIssuedInPeriodExercisePriceOfWarrantsOrRights	0.72
CY2013Q3	isr	Gross Proceeds From Issuance Of Stock GrossProceedsFromIssuanceOfStock	3703527	USD
CY2014Q1	isr	Gross Proceeds From Issuance Of Stock GrossProceedsFromIssuanceOfStock	14675180	USD
	isr	Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares IssuanceOfCommonStockInConnectionWithWarrantExercisesNetOfIssuanceCostsShares	6969829	shares
CY2014Q1	isr	Liability For Common Stock Issuable LiabilityForCommonStockIssuable	35470	USD
CY2013Q3	isr	Payments For Underwriting Fees Costs PaymentsForUnderwritingFeesCosts	185176	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Commission Expense PaymentsOfStockIssuanceCostsCommissionExpense	733759	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Legal And Accounting Expense PaymentsOfStockIssuanceCostsLegalAndAccountingExpense	184514	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Legal And Accounting Expense PaymentsOfStockIssuanceCostsLegalAndAccountingExpense	72494	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Listing Expense PaymentsOfStockIssuanceCostsListingExpense	48500	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Listing Expense PaymentsOfStockIssuanceCostsListingExpense	45000	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Other Expenses PaymentsOfStockIssuanceCostsOtherExpenses	6045	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Other Expenses PaymentsOfStockIssuanceCostsOtherExpenses	5000	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	-18779	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	32174	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	432566	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	609761	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	923780	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	805326	USD
CY2013Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	107578	USD
CY2014Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	117971	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57431293	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80980664	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	23056	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	21036	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13433	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27580	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65217	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85369	USD
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	52598	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	71377	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3029948	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4328170	shares
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	55109	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	50383	USD
CY2013Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	792242	USD
CY2014Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	847351	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23702901	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3684214	USD
CY2013Q2	us-gaap	Assets Assets	7055356	USD
CY2014Q1	us-gaap	Assets Assets	27199964	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	4443660	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	25107326	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2672711	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2899927	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20802974	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1011503	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	193000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34618517	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54181444	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.38
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.14
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1957033	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	646811	shares
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34618517	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54181444	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38419502	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41540982	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	34618	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	54181	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1478703	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1083413	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1065574	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3329950	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3276314	USD
CY2013Q3	us-gaap	Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued	25150	USD
CY2013Q3	us-gaap	Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued	6906	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	517548	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	563850	USD
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	104000	USD
CY2014Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	678000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	177195	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-21525	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-99675	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-67195	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0px" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify"> <td style="WIDTH: 0in"> </td> <td style="WIDTH: 0.5in; TEXT-ALIGN: left"><strong>2.</strong></td> <td style="TEXT-ALIGN: justify"><strong>New Accounting Pronouncements</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong> </strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") or other standards setting bodies that are adopted by us as of the specified effective dates. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position, results of operations and cash flows upon adoption.</p> <!--EndFragment--></div> </div>
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	127419	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	87660	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P10M13D
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	29192	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	640732	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	564075	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1805732	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1678487	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	50906	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	185904	USD
	us-gaap	Gross Profit GrossProfit	-60308	USD
	us-gaap	Gross Profit GrossProfit	6853	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-39759	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-54654	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-18551	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-87368	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	49752	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	27500	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	30301	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	36000	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	10393	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	12961	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4516	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2204	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2213	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69427	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	45	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	104	USD
CY2014Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense		USD
CY2013Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense		USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	827	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	6	USD
CY2013Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	42577	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	39906	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	405571	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	387020	USD
CY2013Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2014Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2013Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	167671	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	165657	USD
CY2013Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	195323	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	181457	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	556	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	83	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1391	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	355	USD
CY2013Q2	us-gaap	Liabilities Liabilities	1689110	USD
CY2014Q1	us-gaap	Liabilities Liabilities	2546101	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7055356	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27199964	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7974	USD
CY2014Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2013Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7974	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-715037	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4281317	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2863032	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2086097	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-717695	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5015669	USD
	us-gaap	Operating Expenses OperatingExpenses	3053234	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-988995	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-824120	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3267881	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3046381	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	792868	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1020750	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23063717	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3294479	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21546	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13030	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2239197	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2269946	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2083439	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2871006	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1094444	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	109083	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1013436	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	183349	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	1039901	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	1010024	USD
	us-gaap	Operating Expenses OperatingExpenses	3207573	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25305	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	75057	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	276507	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258619	USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	100000	USD
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	130301	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5168	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12926	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16333	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2324072	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium		USD
CY2013Q1	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium		USD
	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	726378	USD
	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium		USD
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	59	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	59	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	214382	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212079	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13818927	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3291977	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1478703	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1800589	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3279292	USD
CY2014Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13818927	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15129	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11309	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5961001	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1825	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1684282	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1183067	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	153611	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	155137	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	470631	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	445785	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181149	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181194	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52091334	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56372651	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1134319	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1251478	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3269642	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3283167	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	65000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2050334	USD
CY2014Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	245558	USD
CY2013Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	290812	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	931210	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	928962	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	65217	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	85369	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.58
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.59
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3231	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3231	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0185	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0177	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2040732	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.93
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15130	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13866	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	31700	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1714527	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1923611	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2238840	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.86
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y2M23D
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.58
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.59
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	5366246	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	24653863	USD
	us-gaap	Stock Issued1 StockIssued1	440000	USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26333	shares
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1095000	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	109000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1014000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	183000	USD
CY2014Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	678000	USD
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	131000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42506077	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34611517	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38852980	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34359567	shares

Files In Submission

Name	View Source	Status
0001144204-14-031366-index-headers.html	Edgar Link	pending
0001144204-14-031366-index.html	Edgar Link	pending
0001144204-14-031366.txt	Edgar Link	pending
0001144204-14-031366-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isr-20140331.xml	Edgar Link	completed
isr-20140331.xsd	Edgar Link	pending
isr-20140331_cal.xml	Edgar Link	unprocessable
isr-20140331_def.xml	Edgar Link	unprocessable
isr-20140331_lab.xml	Edgar Link	unprocessable
isr-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v377851_10q.htm	Edgar Link	pending
v377851_ex31-1.htm	Edgar Link	pending
v377851_ex31-2.htm	Edgar Link	pending
v377851_ex32.htm	Edgar Link	pending
v377851_ex4-32.htm	Edgar Link	pending
v377851_ex4-33.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2014 Q2 Form 10-Q Financial Statement

#000114420414031366 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2014 Q2 Form 10-Q Financial Statement

#000114420414031366 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx